AR082887A1 - Derivados de piridin-3-il-metil, y composiciones para la inhibicion de nampt - Google Patents

Derivados de piridin-3-il-metil, y composiciones para la inhibicion de nampt

Info

Publication number
AR082887A1
AR082887A1 ARP110103220A ARP110103220A AR082887A1 AR 082887 A1 AR082887 A1 AR 082887A1 AR P110103220 A ARP110103220 A AR P110103220A AR P110103220 A ARP110103220 A AR P110103220A AR 082887 A1 AR082887 A1 AR 082887A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocycloalkyl
aryl
cycloalkyl
haloalkyl
Prior art date
Application number
ARP110103220A
Other languages
English (en)
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of AR082887A1 publication Critical patent/AR082887A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)

Abstract

Reivindicación 1: Compuestos de la fórmula (1) en donde: Ra es 1, 2, 3 ó 4 y pueden seleccionarse del grupo que consiste en hidrógeno, amino, oxo, halo, alcoxi, alquilo, haloalquilo, -N(alquil)2, -NH(CO)O-alquilo, 1H-pirazol, 1H-imidazol, y -C(O)NH2; y en donde dicha piridina puede comprender un N-óxido formado con su miembro N atómico; R1 es -NR3R4 en donde R3 es H, alquilo o -S(O)2alquilo y R4 es alquilo, hidroxialquilo, -S(O)2alquilo, -(CH2)q-cicloalquilo, -(CH2)q-heterocicloalquilo, arilo, arilalquilo-, -(CH2)q-heteroarilo; haloalquilo; cicloalquilo; arilo; heterocicloalquilo; o heteroarilo; en donde cada uno de dicho cicloalquilo, arilo, heterocicloalquilo o heteroarilo no está sustituido o está sustituido con 1, 2, 3, 4 ó 5 sustituyentes que pueden ser iguales o diferentes y se seleccionan en forma independiente del grupo que consiste en: halo, ciano, alquilo, hidroxilo, hidroxialquilo, hidroxialcoxi, haloalquilo, alcoxi, alquilalcoxi, haloalcoxi, arilalquenilo-, ariloxi, benciloxi, oxo, -(CH2)q-NRbRc, -(CH2)q-CONRbRc, -S(O)2-alquilo, -S(O)2NH-alquilo, -S(O)2-heterocicloalquilo, -S(O)2-CF3, -C(O)alquilo, -C(O)arilo, -C(O)alquilenilarilo, -C(O)O-alquilo, -(CH2)q-cicloalquilo, cicloalquilalcoxi-, arilo, arilalquilo-, -(CH2)q-heteroarilo, y -(CH2)q-heterocicloalquilo; en donde cada uno de dicho cicloalquilo, heterocicloalquilo, arilo o heteroarilo puede estar sustituido por uno o más halo, nitro, haloalquilo, haloalcoxi, oxo, ciano, alquilo, haloalquilo, o alcoxi; Rb y Rc se seleccionan en forma independiente del grupo que consiste en H, alquilo, hidroxialquilo, alcoxi, arilo, alcoxialquilo, -S(O)2alquilo y cicloalquilo; o Rb y Rc pueden formar un grupo heterocicloalquilo de 5 o 6 miembros junto con el átomo de nitrógeno al cual están unidos, en donde dicho grupo heterocicloalquilo puede contener uno o más heteroátomo(s) adicional(es) seleccionado(s) de N, S u O; q es 0 ó 1; y sales aceptables desde el punto de vista farmacéutico de los anteriores, con la salvedad de que los compuestos de la fórmula (1) no sean: N-[4-(fenilsulfonil)fenil]-N’-(3-piridinilmetil)urea; N,N-dietil-4-[[[(3-piridinilmetil)amino]carbonil]amino]bencensulfonamida; o 4-[[[(3-piridinilmetil)amino]carbonil]amino]bencensulfonamida.
ARP110103220A 2010-09-03 2011-09-02 Derivados de piridin-3-il-metil, y composiciones para la inhibicion de nampt AR082887A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37981910P 2010-09-03 2010-09-03
US37981210P 2010-09-03 2010-09-03
US38603710P 2010-09-24 2010-09-24
US38604410P 2010-09-24 2010-09-24
US201161478995P 2011-04-26 2011-04-26
US201161480423P 2011-04-29 2011-04-29

Publications (1)

Publication Number Publication Date
AR082887A1 true AR082887A1 (es) 2013-01-16

Family

ID=44653564

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103220A AR082887A1 (es) 2010-09-03 2011-09-02 Derivados de piridin-3-il-metil, y composiciones para la inhibicion de nampt

Country Status (13)

Country Link
US (4) US20130273034A1 (es)
EP (1) EP2611777B1 (es)
JP (2) JP6038792B2 (es)
KR (1) KR20130114653A (es)
CN (2) CN106986856A (es)
AR (1) AR082887A1 (es)
AU (1) AU2011295724B2 (es)
BR (1) BR112013004858A8 (es)
CA (1) CA2809391A1 (es)
MX (1) MX342481B (es)
RU (2) RU2016116533A (es)
TW (1) TW201217359A (es)
WO (1) WO2012031196A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013004773B1 (pt) 2010-09-03 2022-05-31 Forma Tm, Llc Compostos, seus usos, e composições para a inibição de nampt
AR082887A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Derivados de piridin-3-il-metil, y composiciones para la inhibicion de nampt
KR20140009251A (ko) 2010-11-15 2014-01-22 애브비 인코포레이티드 Ｎａｍｐｔ 및 ｒｏｃｋ 억제제
JP5872027B2 (ja) 2011-05-09 2016-03-01 フォーマ ティーエム， エルエルシー． ニコチンアミドホスホリボシルトランスフェラーゼ（ｎａｍｐｔ）を阻害するためのピペリジン誘導体および組成物
PT2820008T (pt) 2012-03-02 2017-05-05 Genentech Inc Amidas amido-espirocíclicas e derivados de sulfonamidas
AU2013225530A1 (en) 2012-03-02 2014-09-25 Forma Tm, Llc Amido-benzyl sulfone and sulfoxide derivatives
JP2015516436A (ja) * 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
US9296723B2 (en) 2012-05-11 2016-03-29 Abbvie Inc. NAMPT inhibitors
KR20150007349A (ko) * 2012-05-11 2015-01-20 애브비 인코포레이티드 Nampt 억제제
SG11201408770RA (en) * 2012-06-27 2015-01-29 Alzheimer S Inst Of America Inc Compounds and therapeutic uses thereof
AU2013331626B2 (en) * 2012-10-15 2018-08-02 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014074715A1 (en) * 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
CA2946130A1 (en) 2014-04-18 2015-10-22 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
EP3172205A1 (en) 2014-07-23 2017-05-31 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
CA2974078A1 (en) 2015-01-20 2016-07-28 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
US20180290979A1 (en) * 2015-04-30 2018-10-11 Kyoto University Composition having compound accelerating phosphorylation of ampk as effective component
WO2017024255A1 (en) 2015-08-05 2017-02-09 Metrobiotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3017048C (en) * 2016-03-22 2023-11-07 Helsinn Healthcare Sa Benzenesulfonyl-asymmetric ureas and medical uses thereof
KR101869794B1 (ko) * 2016-07-20 2018-06-21 연세대학교 산학협력단 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물
IL291810A (en) 2016-10-18 2022-06-01 Seagen Inc Targeted administration of nicotinamide adenine dinucleotide reductase pathway inhibitors
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
EP3412651A1 (en) * 2017-06-06 2018-12-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibitors of rac1 and uses thereof for inducing bronchodilatation
MX2020004202A (es) * 2017-10-30 2020-08-13 Neuropore Therapies Inc Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas.
WO2019139869A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
KR101937126B1 (ko) * 2018-06-15 2019-01-10 연세대학교 산학협력단 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물
US11918568B2 (en) 2018-07-05 2024-03-05 Sanford Burnham Prebys Medical Discovery Institute Fused ring compound having urea structure
WO2020191359A1 (en) * 2019-03-21 2020-09-24 Fred Hutchinson Cancer Research Center Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
AU2020311404A1 (en) * 2019-07-11 2022-03-03 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
ES2828464A1 (es) * 2019-11-26 2021-05-26 Univ Murcia Inhibidores de la muerte celular por parthanatos para ser usados en el tratamiento de las enfermedades inflamatorias de la piel
FR3103702B1 (fr) * 2019-11-28 2022-02-11 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
EP4076457A4 (en) * 2019-12-20 2023-11-29 Merck Sharp & Dohme LLC AMIDO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHOD FOR USE THEREOF FOR TREATING HERPES VIRUSES
AU2021398569A1 (en) * 2020-12-11 2023-07-06 Scripps Research Institute, The Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
KR20240020716A (ko) 2021-05-27 2024-02-15 메트로 인터내셔널 바이오테크 엘엘씨 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법
CN113278409B (zh) * 2021-06-22 2022-04-29 西南石油大学 一种高温酸化缓蚀剂
CN114890990B (zh) * 2022-04-13 2024-01-16 中国人民解放军海军军医大学 一种化合物及在制备nampt蛋白自噬降解剂中的应用
CN115286617B (zh) * 2022-06-24 2024-04-30 中国人民解放军海军军医大学 一种靶向降解nampt的protac化合物及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205697A1 (es) 1973-03-19 1976-05-31 Rohm & Haas Nuevos compuestos rodenticidas de 1 - (3 - piridilmetil) - 3 - (4 - substituido fenil o 4-nitronaftil) ureas composicion que los comprende y procedimiento para prepararlos
US3931203A (en) 1973-03-19 1976-01-06 Rohm And Haas Company 3-Pyridylmethyl aryl urea rodenticides
DE2334355A1 (de) 1973-07-06 1975-01-16 Hoechst Ag Diphenylharnstoffderivate und ihre herstellung
US3994905A (en) * 1974-04-11 1976-11-30 Rohm And Haas Company 3-Pyridylmethyl aryl urea rodenticides
US4659724A (en) 1982-12-30 1987-04-21 Union Carbide Corporation Certain 1-[4-(5-cyano-2-pyridyloxy)phenyl-benzoyl ureas having pesticidal properties
DE19624704A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756236A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
GB9904275D0 (en) * 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
DE10053794A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Neue Verwendung für Amino- und Amidosulfonamide
WO2002044156A2 (en) 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
ES2200617B1 (es) * 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
DE10109204A1 (de) 2001-02-26 2002-09-19 4Sc Ag Verbindungen zur Behandlung von Protozoen-Erkrankungen
WO2002070467A1 (en) 2001-02-26 2002-09-12 4Sc Ag Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
AU2002364260A1 (en) 2001-12-31 2003-07-30 Bayer Pharmaceuticals Corporation Avb3 and avb5 integrin antagonists and methods of treating diseases or conditions associated with avb3 and avb5 integrins
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
EP1684762A4 (en) 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006113650A1 (en) 2005-04-18 2006-10-26 Khan Saeed R Design and synthesis of novel tubulin polymerization inhibitors: bonzoylphenyluria (bpu) sulfur analogs
BRPI0617513A2 (pt) 2005-10-20 2011-07-26 Sumitomo Chemical Co compostos de benzoilurÉia, processo para a produÇço e uso dos mesmos e mÉtodo para controlar pestes
CN101516838A (zh) 2006-09-28 2009-08-26 亚瑞特医疗公司 可溶性环氧化物水解酶抑制剂
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
CN102186822A (zh) * 2008-08-29 2011-09-14 顶标公司 新脲和硫脲衍生物
FR2943669B1 (fr) 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
MX2011013134A (es) * 2009-06-09 2012-03-16 Topotarget As Derivados de piridinil como inhibidores de la enzima nicotinamida fosforribosiltransferasa.
CA2791680A1 (en) * 2010-03-01 2011-09-09 Myrexis, Inc. Compounds and therapeutic uses thereof
BR112013004773B1 (pt) 2010-09-03 2022-05-31 Forma Tm, Llc Compostos, seus usos, e composições para a inibição de nampt
AR082887A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Derivados de piridin-3-il-metil, y composiciones para la inhibicion de nampt
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
RU2017112522A (ru) 2011-05-04 2019-01-24 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
JP5872027B2 (ja) 2011-05-09 2016-03-01 フォーマ ティーエム， エルエルシー． ニコチンアミドホスホリボシルトランスフェラーゼ（ｎａｍｐｔ）を阻害するためのピペリジン誘導体および組成物
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
EP2820017B1 (en) 2012-03-02 2016-12-21 Genentech, Inc. Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
PT2820008T (pt) 2012-03-02 2017-05-05 Genentech Inc Amidas amido-espirocíclicas e derivados de sulfonamidas
WO2013130935A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfoxide derivatives
WO2013127268A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
AU2013225530A1 (en) 2012-03-02 2014-09-25 Forma Tm, Llc Amido-benzyl sulfone and sulfoxide derivatives

Also Published As

Publication number Publication date
BR112013004858A2 (pt) 2016-06-07
KR20130114653A (ko) 2013-10-17
AU2011295724B2 (en) 2016-05-12
CA2809391A1 (en) 2012-03-08
JP6038792B2 (ja) 2016-12-07
TW201217359A (en) 2012-05-01
US20200283403A1 (en) 2020-09-10
CN103270023A (zh) 2013-08-28
CN103270023B (zh) 2016-11-02
US20190270721A1 (en) 2019-09-05
RU2016116533A (ru) 2018-11-30
WO2012031196A9 (en) 2013-06-13
RU2617424C2 (ru) 2017-04-25
US10329275B2 (en) 2019-06-25
US20180291000A1 (en) 2018-10-11
US20130273034A1 (en) 2013-10-17
RU2016116533A3 (es) 2018-11-30
BR112013004858A8 (pt) 2018-01-02
AU2011295724A1 (en) 2013-05-02
EP2611777A1 (en) 2013-07-10
EP2611777B1 (en) 2016-05-11
MX2013002431A (es) 2013-06-03
CN106986856A (zh) 2017-07-28
US11279687B2 (en) 2022-03-22
RU2013114844A (ru) 2014-10-10
WO2012031196A1 (en) 2012-03-08
US10647695B2 (en) 2020-05-12
AU2011295724A8 (en) 2013-06-20
MX342481B (es) 2016-09-30
JP2013536868A (ja) 2013-09-26
JP2017019825A (ja) 2017-01-26

Similar Documents

Publication Publication Date Title
AR082887A1 (es) Derivados de piridin-3-il-metil, y composiciones para la inhibicion de nampt
AR082888A1 (es) Compuestos de piridina para la inhibicion de nampt
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
AR057979A1 (es) PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
MX2020005874A (es) Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa).
AR073412A1 (es) Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende.
AR068950A1 (es) Derivados heterociclo biciclicos y metodos de uso de los mismos
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
PE20212253A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
AR039665A1 (es) Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa
AR082681A1 (es) Inhibidores del virus de la hepatitis c
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
AR066120A1 (es) Derivados de pirimidinona y sus metodos de uso
AR038834A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco
ES2601518T3 (es) Composiciones plaguicidas
AR047533A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa
AR053728A1 (es) Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos
PE20060721A1 (es) Serinamidas sustituidas por heteroaroilo
AR046445A1 (es) Derivados de piridazin-3(2h)-ona
AR110992A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
AR059094A1 (es) Derivados de ciclohexil - sulfonamida
AR086590A1 (es) Compuestos de ciclohexanona y herbicidas que los comprenden
UA99637C2 (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащее их противогрибковое средство

Legal Events

Date Code Title Description
FB Suspension of granting procedure